The treatment in question is a so-called PrEP drug called Truvada and, if actually enacted, could equate to several million bottles being given out to uninsured patients at high risk of contracting HIV.
The pledge may last up to 11 years, said HHS Secretary Alex Azar. According to the article, the study looked at multiple databases in which outpatient drug use information for medications covered by state Medicaid agencies is recorded, as well as opioid mortality figures from the National Center for Health Statistics System for 2005 to 2016.
On Thursday, President Trump, who stated in February that his administration had a goal to end the HIV epidemic in the United States within 10 years, announced that his administration had successfully worked with a pharmaceutical company to initiate a historic donation to eliminating the HIV problem in America.
Gilead Sciences is the creator of Truvada.
HIV-preventing PrEP drugs will be made available for free to 200,000 people in the USA, it has been announced.
The advocacy group PrEP4All, responding to Azar's announcement on Twitter, said Gilead's donation is still not enough to properly address the AIDS crisis in the U.S. But it also hits on the reality that, despite Truvada's existence, thousands upon thousands of patients who could benefit from it don't have the financial resources to do so (it can cost close to $2,000 per month out of pocket).
In a statement, Gilead's Chief Patent Officer Gregg Alton said they are proud to partner with the CDC to increase the public's access to treatment that can help prevent new HIV cases.
The drug maker believes the Truvada donation, combined with efforts to curb the root causes of HIV, such as homophobia, racism, stigma, transphobia, and violence against women, can lead to the end of disease transmission in the United States.